CanSino Biologics Inc. (6185.HK)
HKD 33.5
(-1.33%)
HKD 33.5
(-1.33%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 2.7 Billion CNY | -0.01% |
| 2022 | 2.7 Billion CNY | 96.44% |
| 2021 | 1.37 Billion CNY | 864.53% |
| 2020 | 142.53 Million CNY | -14.55% |
| 2019 | 166.79 Million CNY | 11.2% |
| 2018 | 150 Million CNY | 38.46% |
| 2017 | 108.33 Million CNY | 56.26% |
| 2016 | 69.32 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 2.11 Billion CNY | -21.58% |
| 2024 Q2 | 2.19 Billion CNY | 3.75% |
| 2023 Q2 | 2.44 Billion CNY | -10.08% |
| 2023 FY | 2.7 Billion CNY | -0.01% |
| 2023 Q4 | 2.7 Billion CNY | 36.67% |
| 2023 Q3 | 1.97 Billion CNY | -19.13% |
| 2023 Q1 | 2.71 Billion CNY | 0.61% |
| 2022 Q2 | 2.13 Billion CNY | 39.16% |
| 2022 FY | 2.7 Billion CNY | 96.44% |
| 2022 Q4 | 2.7 Billion CNY | 11.63% |
| 2022 Q3 | 2.41 Billion CNY | 13.3% |
| 2022 Q1 | 1.53 Billion CNY | 11.62% |
| 2021 Q4 | 1.37 Billion CNY | 17.29% |
| 2021 Q1 | 519.02 Million CNY | 264.13% |
| 2021 Q2 | 900.07 Million CNY | 73.42% |
| 2021 Q3 | 1.17 Billion CNY | 30.23% |
| 2021 FY | 1.37 Billion CNY | 864.53% |
| 2020 Q4 | 142.53 Million CNY | -1.55% |
| 2020 FY | 142.53 Million CNY | -14.55% |
| 2020 Q2 | 154.55 Million CNY | -1.5% |
| 2020 Q3 | 144.78 Million CNY | -6.32% |
| 2020 Q1 | 156.9 Million CNY | -5.93% |
| 2019 Q4 | 166.79 Million CNY | 0.0% |
| 2019 FY | 166.79 Million CNY | 11.2% |
| 2019 Q2 | 171.17 Million CNY | 0.0% |
| 2019 Q1 | - CNY | -100.0% |
| 2018 FY | 150 Million CNY | 38.46% |
| 2018 Q1 | - CNY | 0.0% |
| 2018 Q3 | 150 Million CNY | 0.0% |
| 2018 Q4 | 150 Million CNY | 0.0% |
| 2017 FY | 108.33 Million CNY | 56.26% |
| 2016 FY | 69.32 Million CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 6.8 Million HKD | -39552.59% |
| Grand Pharmaceutical Group Limited | 3.4 Billion HKD | 20.677% |
| Extrawell Pharmaceutical Holdings Limited | 120.41 Million HKD | -2142.622% |
| Wai Yuen Tong Medicine Holdings Limited | 460.94 Million HKD | -485.822% |
| Qianhai Health Holdings Limited | 487 Thousand HKD | -554384.805% |
| Lee's Pharmaceutical Holdings Limited | 204.14 Million HKD | -1222.789% |
| Essex Bio-Technology Limited | 294.02 Million HKD | -818.414% |
| Tongfang Kontafarma Holdings Limited | 333.82 Million HKD | -708.914% |
| PuraPharm Corporation Limited | 424.77 Million HKD | -535.718% |
| SSY Group Limited | 3.37 Billion HKD | 19.968% |
| JBM (Healthcare) Limited | 133.4 Million HKD | -1924.137% |
| Jacobson Pharma Corporation Limited | 749.37 Million HKD | -260.344% |
| China Resources Pharmaceutical Group Limited | 85.84 Billion HKD | 96.854% |